• ISIN: DE000A3CMGM5
  • Land: Deutschland

Nachricht vom 18.06.2021 | 07:30

APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

DGAP-News: APONTIS PHARMA AG / Key word(s): Research Update
18.06.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

Monheim am Rhein, 18 June 2021.
The analysts at Hauck & Aufhäuser and Warburg Research have initiated coverage of the APONTIS PHARMA AG share (Ticker APPH / ISIN DE000A3CMGM5). In their initial study, the experts attest APONTIS an early-mover advantage in the market for Single Pills, which the company can convert into market share by accelerating the development of its broad product pipeline thanks to the fresh funds from the IPO, among other things.

Accordingly, Hauck & Aufhäuser analyst Aliaksandr Halitsa expects consolidated sales to grow by an average of 20% per year to EUR 96 million by the 2025 financial year, driven by market share gains and new products from the Single Pill pipeline. Due to the high scalability, the experts expect EBIT to increase to EUR 27 million in the same period, which corresponds to an EBIT margin of 28%.

Based on a DCF model, Hauck & Aufhäuser sees a price target of EUR 31.00. From the current price level of EUR 17.50, this corresponds to a price potential of 77%.

Warburg Research is even more confident in its initial assessment. The favorable global market trends such as the expanding Single Pill submarket, an aging society, the increasing relevance of combination therapies and stagnating R&D innovations in the industry provide APONTIS PHARMA with high growth potential, according to the experts.

The company currently has eight Single Pill products in its portfolio and has already achieved impressive growth rates of 250% to 800% with these products since market launch, according to Warburg analyst Dr. Christian Ehmann. Continuing on this path, APONTIS has four products in the short-term and 12 further projects for medium-term market entry in the pipeline, the expert added.

The Warburg analyst estimates sales of EUR 108.3 million by 2025 and considers an EBITDA of EUR 31.7 million to be achievable. Based on the current forecasts, Warburg Research derives a price target of EUR 41.00, which corresponds to a price potential of 135% based on the DCF model. The contact details of the analysts are available at the following link: https://ir.apontis-pharma.de/websites/apontispharma/English/2000/share-price.html


APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.


Investor Relations
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein


Sven Pauly
Sara Pinto
T: +49 89 125 09 0330

18.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

23. September 2021